Results 91 to 100 of about 2,329 (147)

Efficacy and safety of ozanimod in multiple sclerosis : Dose-blinded extension of a randomized phase II study

Altres ajuts: The study was sponsored by Celgene Corporation.Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. In the
Cree, Bruce AC, Bar-Or, Amit, Steinman, Lawrence, Havrdová, Eva K, Comi, Giancarlo, Kappos, Ludwig, Selmaj, Krzysztof W, Montalbán, Xavier, Huang, Vivian, Skolnick, Brett E, Arnold, Douglas L, Hartung, Hans-Peter, Cohen, Jeffrey A, Frohna, Paul   +13 more
core  

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

Annals of Clinical and Translational Neurology
Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory
Faizan Shahzad, Taimoon Rasheed, Momina Riaz Siddiqui, Hamza Hamid, Marwah Bintay Khalid, Haroon Shabbir, Besher Shami, Abdullah, Syed Ijlal Ahmed   +8 more
doaj   +1 more source

Ketogenic diet-induced changes in hepatic drug metabolism with potential implications for ozanimod pharmacokinetics in mice. [PDF]

PLoS One
Frybortova V, Satka S, Jourova L, Anzenbacher P, Zapletalova I, Kraus M, Kostovcikova K, Kverka M, Anzenbacherova E.   +8 more
europepmc   +1 more source

Cardiac arrhythmias associated with S1PRMs: a pharmacovigilance study based on real-world data. [PDF]

Front Pharmacol
Wang S, Xie L, Ma P.
europepmc   +1 more source

Comprehensive Analysis of Ozanimod-Related Adverse Events Based on the FAERS Database. [PDF]

World J Oncol
Zhou ZR, Zhou QY, Shen Y, Zhao XY, Zhan Q, Sun J, Chen ZX.   +6 more
europepmc   +1 more source

Influence of Ageing on the Pharmacology, Efficacy and Safety of Oral Targeted Therapies for Inflammatory Bowel Disease: Focus on Janus Kinase (JAK) Inhibitors and Sphingosine-1-Phosphate (S1P) Receptor Modulators. [PDF]

Drugs Aging
Derijks LJJ, Karapinar-Çarkit F, Mujagić Z, van Marum RJ, Pierik MJ.   +4 more
europepmc   +1 more source

Effects of sphingosine-1-phosphate receptor modulators on remyelination in multiple sclerosis: evidence from <i>in vitro</i> experiments, animal models and human studies. [PDF]

Front Immunol
Ricigliano VAG.
europepmc   +1 more source

Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis. [PDF]

Int J Mol Sci
Costa-Frossard L, Brieva L, García-Estévez DA, Martín-Martínez JM, Álvarez-Bravo G, Blasco-Quílez MR, Meca-Lallana JE, Calles-Hernández MC, Ramo Tello C, Muñoz-Fernández C, Barbero DE, López-Muñoz P, Prieto González JM, Candeliere-Merlicco A, Carmona O, Riancho J, Sola-Valls N, Carcelén-Gadea M, Borrega L, Gascón-Giménez F, Vilanova D, Pérez X, Villar LM.   +22 more
europepmc   +1 more source

Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. [PDF]

Inflamm Bowel Dis
Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, Petersen A, Liu Z, Mehra D, Jain A, Osterman MT, Krakovich A, Riolo JV, DeBoer E, Appio J, Sinh P, Cree BAC, Cohen JA, Irving P.   +18 more
europepmc   +1 more source

A Delicate Balance: Immunotherapy for Endometrial Cancer in a Patient With Multiple Sclerosis. [PDF]

J Med Cases
Ruggiero A, Redemagni C, Camnasio CA, Morteo V, Carcagni F, Zatti S, Strada I, Roccio M, Rigoni E, Cassani C, Colombo E.   +10 more
europepmc   +1 more source